Dianthus Therapeutics (DNTH) Current Deferred Revenue (2022 - 2025)
Historic Current Deferred Revenue for Dianthus Therapeutics (DNTH) over the last 4 years, with Q3 2025 value amounting to $954000.0.
- Dianthus Therapeutics' Current Deferred Revenue rose 85400.0% to $954000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $954000.0, marking a year-over-year increase of 85400.0%. This contributed to the annual value of $479000.0 for FY2024, which is N/A changed from last year.
- Per Dianthus Therapeutics' latest filing, its Current Deferred Revenue stood at $954000.0 for Q3 2025, which was up 85400.0% from $479000.0 recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' Current Deferred Revenue registered a high of $954000.0 during Q3 2025, and its lowest value of $100000.0 during Q4 2022.
- For the 4-year period, Dianthus Therapeutics' Current Deferred Revenue averaged around $321222.2, with its median value being $100000.0 (2022).
- Per our database at Business Quant, Dianthus Therapeutics' Current Deferred Revenue changed by 0.0% in 2024 and then surged by 85400.0% in 2025.
- Dianthus Therapeutics' Current Deferred Revenue (Quarter) stood at $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then soared by 379.0% to $479000.0 in 2024, then surged by 99.16% to $954000.0 in 2025.
- Its Current Deferred Revenue was $954000.0 in Q3 2025, compared to $479000.0 in Q2 2025 and $479000.0 in Q1 2025.